Technology - CD Formulation

Advances Platform for Gene Therapy Formulation Development

CD Formulation has established various advanced and complete technology platforms, including ligand-conjugated antisense technology, siRNA technology, lipid nanoparticle delivery systems, etc. We work with investigators to advance research in developing gene therapy formulations designed to meet the most demanding and critical needs in basic research and preclinical applications.

Ligand-Conjugated Antisense Technology Services

Ligand-conjugated antisense technology is a powerful tool used in gene therapy formulation development. Antisense technology involves the use of short nucleic acid sequences, known as antisense oligonucleotides (ASOs), which bind to target RNA molecules, thereby modulating gene expression. Ligand conjugation refers to the attachment of specific ligands (molecules) to ASOs, enabling targeted delivery to specific cells or tissues.

siRNA Technology Services

Small interfering RNA (siRNA) technology can selectively silence gene expression by targeting and degrading specific mRNA molecules. Using siRNAs as a treatment for hereditary diseases could provide a promising approach by specifically silencing disease-causing genes. By enhancing siRNA delivery, the platform increases the therapeutic potential of gene therapies targeting gene silencing.

Gene Synthesis Technology Services

After years of research, we have continuously optimized and upgraded our technology system to overcome the limitations of traditional gene synthesis technology in developing and applying gene therapy formulations. Our gene synthesis technology can accurately design and sequence target genes according to customer needs, and we have helped researchers complete several cases of gene synthesis optimization to accelerate the development of high-quality gene therapy formulations.

Comprehensive Formulation Development

Our technology platform provides a comprehensive approach to gene therapy formulation development. We offer expertise in formulating various types of gene therapy formulations, including nucleic acids (such as antisense oligonucleotides, siRNAs, and mRNA) and gene editing tools (such as CRISPR/Cas9).

Enhanced Delivery Systems

Using our technology platform, we can deliver gene therapy formulations efficiently and precisely to desired cells or tissues. We utilize cutting-edge approaches such as lipid nanoparticles, viral vectors, polymeric vectors, and ligand-coupled systems to optimize delivery efficiency and enhance therapeutic efficacy.

Customized Formulation Optimization

Our technology platform allows for custom formulation optimization, taking into account factors such as stability, delivery efficiency, target tissue specificity and immunogenicity. We use advanced formulation technologies and state-of-the-art equipment to customize formulations to meet the specific needs of each gene therapy drug.